PMID- 31525642
OWN - NLM
STAT- MEDLINE
DCOM- 20200225
LR  - 20200225
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 119
DP  - 2019 Nov
TI  - Hsa_circ_0042666 inhibits proliferation and invasion via regulating 
      miR-223/TGFBR3 axis in laryngeal squamous cell carcinoma.
PG  - 109365
LID - S0753-3322(19)33335-9 [pii]
LID - 10.1016/j.biopha.2019.109365 [doi]
AB  - Circular RNAs (circRNAs) have been reported to play critical roles in 
      tumorigenesis. However, the roles of circRNAs in laryngeal squamous cell 
      carcinoma (LSCC) are still largely unknown. In our present study, we identified a 
      novel circRNA hsa_circ_0042666, which was poorly expressed in LSCC. Low 
      hsa_circ_0042666 expression was closely associated with advanced tumor stage, 
      lymph-node metastasis, and poor overall survival. In vitro function assays, we 
      showed that hsa_circ_0042666 dramatically reduced LSCC cells proliferation and 
      invasion in vitro. In mechanism, our data indicated that hsa_circ_0042666 could 
      competitively bind to miR-223 as a miRNA sponge to regulate TGFBR3 expression in 
      LSCC progression. Altogether, these findings elucidated that hsa_circ_0042666 
      regulated LSCC cells proliferation and invasion by miR-223/TGFBR3 axis, which 
      might provide a therapeutic strategy for the treatment of LSCC.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Wei, Zhenxing
AU  - Wei Z
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Luoyang Central Hospital 
      Affiliated to Zhengzhou University, Luoyang 471000, Henan, China. Electronic 
      address: weizhenxingwzx@163.com.
FAU - Chang, Kunpeng
AU  - Chang K
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Luoyang Central Hospital 
      Affiliated to Zhengzhou University, Luoyang 471000, Henan, China.
FAU - Fan, Chongsheng
AU  - Fan C
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Luoyang Central Hospital 
      Affiliated to Zhengzhou University, Luoyang 471000, Henan, China.
LA  - eng
PT  - Journal Article
DEP - 20190913
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (MIRN223 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Proteoglycans)
RN  - 0 (RNA, Circular)
RN  - 0 (Receptors, Transforming Growth Factor beta)
RN  - 145170-29-2 (betaglycan)
SB  - IM
MH  - Aged
MH  - Base Sequence
MH  - Carcinoma, Squamous Cell/*genetics/*pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Disease Progression
MH  - Down-Regulation/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/*pathology
MH  - Male
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Proteoglycans/genetics/*metabolism
MH  - RNA, Circular/genetics/*metabolism
MH  - Receptors, Transforming Growth Factor beta/genetics/*metabolism
OTO - NOTNLM
OT  - LSCC
OT  - TGFBR3
OT  - hsa_circ_0042666
OT  - miR-223
EDAT- 2019/09/17 06:00
MHDA- 2020/02/26 06:00
CRDT- 2019/09/17 06:00
PHST- 2019/07/10 00:00 [received]
PHST- 2019/07/31 00:00 [revised]
PHST- 2019/08/14 00:00 [accepted]
PHST- 2019/09/17 06:00 [pubmed]
PHST- 2020/02/26 06:00 [medline]
PHST- 2019/09/17 06:00 [entrez]
AID - S0753-3322(19)33335-9 [pii]
AID - 10.1016/j.biopha.2019.109365 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2019 Nov;119:109365. doi: 10.1016/j.biopha.2019.109365. Epub 
      2019 Sep 13.